research Cutaneous Drug Delivery: An Update
New methods like nanoparticles and microneedles show promise for better skin drug delivery, especially for hair disorders.
Search
forResearch
5 / 1000+ results 
research Exploring the Versatility of Microemulsions in Cutaneous Drug Delivery: Opportunities and Challenges
Microemulsions could improve skin drug delivery but face challenges like complex creation and potential toxicity.
research Influences of skin barrier, a nanoparticle-based vehicle and solvents on cutaneous drug delivery
Disrupting the skin barrier and using specific nanoparticles and solvents can improve drug delivery through the skin.
research Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil:in vitroevaluation of drug permeation by infrared spectroscopy
PEVs effectively deliver minoxidil through skin.
research Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma — with or without concurrent bimatoprost and/or minoxidil
Laser-assisted delivery of PRP, with or without bimatoprost and minoxidil, can effectively stimulate hair growth.
Community Join
3 / 1000+ resultscommunity New and Interesting HairLoss Studies/Papers/Reviews
Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
community My experimental hair loss journey under medical supervision: finasteride/dutasteride, oral/topical minoxidil+tretinoin (3-month progress and hair transplant insights for those considering it)
A 23-year-old discusses their hair loss treatment using finasteride, dutasteride, oral and topical minoxidil, and topical tretinoin under medical supervision. They stress stabilizing hair loss before a hair transplant and plan to continue the regimen for at least 18 months.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Clinics
1 / 1 resultsLearn
— no results
Experts
— no results